FBR Capital Starts Regulus Therapeutics (RGLS) at Outperform
Tweet Send to a Friend
FBR Capital initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform. PT $15.00.
Analyst William Tanner, Ph.D comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst William Tanner, Ph.D comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE